Pfizer has entered a 'most favored nation' drug pricing agreement with the U.S. government, establishing a precedent for presidential negotiation of pharmaceutical prices. While the deal leaves Pfizer largely unaffected, it introduces a framework that could influence future drug pricing policies and negotiations. This development underscores ongoing political and industry dynamics affecting the pharmaceutical pricing landscape in the United States.